Clinical and Experimental Nephrology

, Volume 23, Issue 12, pp 1357–1363 | Cite as

The association between genotypes of urate transporter-1, Serum uric acid, and mortality in the community-based population: the Yamagata (Takahata) Study

  • Soichiro Kon
  • Tsuneo KontaEmail author
  • Kazunobu Ichikawa
  • Masafumi Watanabe
  • Hidenori Sato
  • Kenichi Ishizawa
  • Yoshiyuki Ueno
  • Hidetoshi Yamashita
  • Takamasa Kayama
Original article



The urate transporter-1 (URAT1) is crucial in developing hyperuricemia via reabsorption of uric acid in renal tubules, and its function is regulated by several single nucleotide polymorphisms (SNPs) within SLC22A12 gene encoding URAT1. This study investigated whether the genetic predisposition of URAT1 is associated with the mortality in general population.


This study enrolled 1596 participants (male 45%, mean age 61 years) who registered at local health checkup in Takahata, Japan, and the association between the rs505802 genotypes in SLC22A12 gene and the 7-year mortality, was examined.


The serum uric acid levels (mean ± SD) at baseline in the subjects with GG and AG + AA genotypes of rs505802 were 5.1 ± 1.3 mg/dL and 5.0 ± 1.5 mg/dL, respectively. Kaplan–Meier analysis revealed that the mortality was nonsignificantly higher in the subjects with GG genotype than in those with AG + AA genotype (P = 0.09). Cox proportional hazard model adjusted with age, gender, renal function, comorbidities, and other possible confounders, demonstrated that the GG genotype was significantly associated with the mortality [hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.05–4.85, (vs. AG + AA genotype)]. Furthermore, adjustment with serum uric acid levels, along with aforementioned confounders retained the significant association (HR 2.26, 95% CI 1.05–4.85).


This study revealed that the genetic predisposition of URAT1 was independently associated with mortality in the Japanese community-based population. This association might be due to the mechanism independent of serum uric acid levels.


Uric acid Mortality SLC22A12 Snps URAT1 



This study was supported in part by a Grant in-Aid from the 21st Century Center of Excellence (COE), Global COE program of the Japan Society for the Promotion of Science, a research grant of the Gout Foundation, Pfizer Inc. and Novartis Research Grants.

Compliance with ethical standards

Conflict of interest

Disclosure of potential conflicts of interest: Honoraria: Konta T (Bayer), Grants received: Konta T (Novartis, Pfizer Inc.).

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number: Yamagata University, 2006–1) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from all individual participants included in the study.

Supplementary material

10157_2019_1781_MOESM1_ESM.pptx (43 kb)
Supplementary Fig. 1. Seven years survival curve by GG/AG+AA genotype in rs505802 in SLC22A12 gene and the presence/absence of hyperuricemia (PPTX 43 kb)


  1. 1.
    Grantham JJ, Chonko AM. Chanpter 13-renal handling of organic anions and cations; excretion of uric acid. In: The kidney, 4th edn. W. B. Saunders, Philadelphia. 1991, pp. 483–509Google Scholar
  2. 2.
    Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Inter Med. 1951;34:1421–31.CrossRefGoogle Scholar
  3. 3.
    Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–21.CrossRefGoogle Scholar
  4. 4.
    Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.CrossRefGoogle Scholar
  5. 5.
    Zhao G, Huang L, Song M, et al. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231:61–8.CrossRefGoogle Scholar
  6. 6.
    Kamei K, Konta T, Ichikawa K, et al. Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study. Clin Exp Nephrol. 2016;20:904–9.CrossRefGoogle Scholar
  7. 7.
    Kamei K, Konta T, Hirayama A, et al. Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study. Clin Exp Nephrol. 2017;21:497–503.CrossRefGoogle Scholar
  8. 8.
    Kamei K, Konta T, Hirayama A, et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014;29:2286–92.CrossRefGoogle Scholar
  9. 9.
    Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–64.CrossRefGoogle Scholar
  10. 10.
    Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55:1293–301.CrossRefGoogle Scholar
  11. 11.
    Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout; a function-based genetic analysis in a Japanese population. Sci Transl Med 2009;1:5ra11Google Scholar
  12. 12.
    Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006;17:1791–5.CrossRefGoogle Scholar
  13. 13.
    Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258–69.CrossRefGoogle Scholar
  14. 14.
    Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293:C584–C596596.CrossRefGoogle Scholar
  15. 15.
    Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricemia and gout. Nat Rev Rheumatol. 2012;8:610–21.CrossRefGoogle Scholar
  16. 16.
    Takeuchi F, Yamamoto K, Isono M, et al. Genetic impact on uric acid concentration and hyperuricemia in the Japanese population. J Atheroscler Thromb. 2013;20:351–67.CrossRefGoogle Scholar
  17. 17.
    Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5:e10000504.CrossRefGoogle Scholar
  18. 18.
    Mohamed S, Richard JJ, Stephen TT, et al. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012;35:477–82.CrossRefGoogle Scholar
  19. 19.
    Konta T, Kudo K, Sato H, et al. Albuminuria is an independent predictor of all-cause and mortality in the Japanese population: the Takahata study. Clin Exp Nephrol. 2013;6:805–10.CrossRefGoogle Scholar
  20. 20.
    Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR form serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefGoogle Scholar
  21. 21.
    Flynn TJ, Phipps-Green A, Hollis-Moffatt JE, et al. Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case- control sample sets reveals multiple ancestral-specific effects. Arthritis Res Ther. 2013;15:R220.CrossRefGoogle Scholar
  22. 22.
    Tu HP, Chung CM, Ko AM, et al. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet. 2016;61:803–10.CrossRefGoogle Scholar
  23. 23.
    Konta T, Emi M, Toriyama S, et al. Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. J Hum Genet. 2008;53:267–74.CrossRefGoogle Scholar
  24. 24.
    Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427:266–72.CrossRefGoogle Scholar
  25. 25.
    Hisatome I. Imapct of serum uric acid level on the cardiovascular system as a risk factor. Folia Pharmacol Jpn. 2010;136:325–9.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Department of Cardiology, Pulmonology and NephrologyYamagata University School of MedicineYamagataJapan
  2. 2.Department of Public Health and HygieneYamagata University Graduate School of Medical ScienceYamagataJapan
  3. 3.Global Center of ExcellenceYamagata University School of MedicineYamagataJapan

Personalised recommendations